指南与共识白血病

专家意见:二代酪氨酸激酶抑制剂耐药后慢性髓性白血病的管理

Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.
指南 / 共识 · Leukemia · 2020-05-04

本文为关于慢性期慢性髓性白血病(CML)患者对二代酪氨酸激酶抑制剂(TKI)耐药后管理的专家意见。文章指出该情形缺乏精确指南与数据,需个体化选择早期异基因造血干细胞移植或后续TKI,并基于细胞遗传学、突变谱、合并症、年龄、既往不良反应史及特定TKI不良反应风险等因素决策。

要点

  • 慢性期CML治疗目标为避免进展至加速期或急变期、避免不良事件并恢复维持生活质量。
  • 对TKI失败患者必须更换治疗以限制进展和死亡风险;二代TKI真正耐药者需更强效治疗。
  • 二代TKI耐药后下一步治疗应个体化,基于细胞遗传学、突变谱、合并症、年龄、既往不良反应史及特定TKI不良反应风险。

核心结论

  • 二代TKI真正耐药的患者需更强效治疗,关键考量是早期异基因造血干细胞移植或使用后续TKI的相对适宜性。

研究设计与样本

  • 本文为专家意见,回顾二代TKI耐药患者的治疗选择并提供临床意见与决策指导。

主要发现

  • 目前尚无针对二代TKI失败患者的精确指南,指导该情形临床决策的数据匮乏。
  • 本文重点讨论因耐药而非因不耐受导致二代TKI失败的患者。

关键数值与推荐

  • 慢性期CML治疗目标为避免进展至加速期或急变期、避免不良事件并恢复维持生活质量。
  • 达到上述目标最重要的预后因素是在关键里程碑时对TKI的应答。
  • 对TKI失败患者必须更换治疗以限制进展和死亡风险。
  • 二代TKI耐药后下一步治疗的选择应个体化,基于细胞遗传学、突变谱、合并症、年龄、既往TKI不良反应史及特定TKI不良反应风险等因素。

临床怎么用

  • 本文与现有推荐不冲突,而是基于新数据、见解和临床经验对既往观念的演进;作者提供临床意见与决策指导。

局限性

  • 目前尚无针对二代TKI失败患者的精确指南。
  • 指导该情形临床决策的数据匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia (CML) are: avoid progression to accelerated phase or blast crisis CML such that patients achieve a life expectancy comparable with that of the general population; avoid adverse events (AEs); and restore and maintain quality of life. The most important prognostic factor for achieving these goals is response to tyrosine kinase inhibitors (TKIs) at key milestones. For patients failing a TKI, a treatment change is mandatory to limit the risk of progression and death. There is currently no precise guideline for patients that fail a second-generation TKI, and there is a paucity of data to guide clinical decision making in this setting. There is, therefore, an unmet need for practical and actionable guidance on how to manage patients who fail a second-generation TKI. Although the term 'failure' includes patients failing for resistance or intolerance, the focus of this paper is failure of a second-generation TKI because of resistance. CML patients who fail their first second-generation TKI for true resistance need a more potent therapy. In these patients, the key issues to consider are the relative appropriateness of early allogeneic hematopoietic stem cell transplantation or the use of a further TKI. Selection of the next line of treatment after second-generation TKI resistance should be individualized and must be based on patient-specific factors including cytogenetics, mutation profile, comorbidities, age, previous history of AEs with prior TKI therapy, and risk profile for AEs on specific TKIs. This expert opinion paper is not in conflict with existing recommendations, but instead represents an evolution of previous notions, based on new data, insights, and clinical experience. We review the treatment options for patients resistant to second-generation TKI therapy and provide our clinical opinions and guidance on key considerations for treatment decision making.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hochhaus A, Breccia M, Saglio G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020. PMID: 32366938. doi:10.1038/s41375-020-0842-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。